All In Biotech

Drug Trial Radar · NCT07196501

A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI-1065845 as an Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Aug 18, 2025

Primary completion

Jul 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Sep 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.

Conditions

  • Major Depressive Disorder

Interventions

  • OsavampatorDrug

    Oral tablet

  • PlaceboDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from Randomization to RelapseTime frame: From randomization to the earliest of relapse or end-of study (up to approximately 32 months)

Locations

61 sites in 11 countries. Site status is shown where the registry gives one.

  • Neurocrine Clinical Site

    Oceanside, California · Recruiting

  • Neurocrine Clinical Site

    Orange, California · Recruiting

  • Neurocrine Clinical Site

    San Jose, California · Recruiting

  • Neurocrine Clinical Site

    New Haven, Connecticut · Recruiting

  • Neurocrine Clinical Site

    Miami Gardens, Florida · Recruiting

  • Neurocrine Clinical Site

    Orlando, Florida · Recruiting

  • Neurocrine Clinical Site

    Palm Bay, Florida · Recruiting

  • Neurocrine Clinical Site

    Tampa, Florida · Recruiting

  • Neurocrine Clinical Site

    Iowa City, Iowa · Recruiting

  • Neurocrine Clinical Site

    Marrero, Louisiana · Recruiting

  • Neurocrine Clinical Site

    O'Fallon, Missouri · Recruiting

  • Neurocrine Clinical Site

    Albuquerque, New Mexico · Active not recruiting

  • Neurocrine Clinical Site

    Glen Oaks, New York · Recruiting

  • Neurocrine Clinical Site

    Charlotte, North Carolina · Recruiting

  • Neurocrine Clinical Site

    Edmond, Oklahoma · Recruiting

  • Neurocrine Clinical Site

    Oklahoma City, Oklahoma · Recruiting

  • Neurocrine Clinical Site

    Philadelphia, Pennsylvania · Recruiting

  • Neurocrine Clinical Site

    Austin, Texas · Active not recruiting

  • Neurocrine Clinical Site

    Bellaire, Texas · Recruiting

  • Neurocrine Clinical Site

    Friendswood, Texas · Terminated

  • Neurocrine Clinical Site

    Stafford, Texas · Recruiting

  • Neurocrine Clinical Site

    Wichita Falls, Texas · Active not recruiting

  • Neurocrine Clinical Site

    Draper, Utah · Recruiting

  • Neurocrine Clinical Site

    Roanoke, Virginia · Recruiting

  • Neurocrine Clinical Site

    Carlton, Victoria, Australia · Recruiting

  • Neurocrine Clinical Site

    Melbourne, Victoria, Australia · Recruiting

  • Neurocrine Clinical Site

    Parkville, Victoria, Australia · Recruiting

  • Neurocrine Clinical Site

    Sofia, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Sofia, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Sofia, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Sofia, Bulgaria · Recruiting

  • Neurocrine Clinical Site

    Toronto, Canada · Recruiting

  • Neurocrine Clinical Site

    Calgary, Alberta, Canada · Recruiting

  • Neurocrine Clinical Site

    North Vancouver, British Columbia, Canada · Recruiting

  • Neurocrine Clinical Site

    Kingston, Ontario, Canada · Recruiting

  • Neurocrine Clinical Site

    Sherbrooke, Quebec, Canada · Active not recruiting

  • Neurocrine Clinical Site

    Tallinn, Estonia · Recruiting

  • Neurocrine Clinical Site

    Tallinn, Estonia · Recruiting

  • Neurocrine Clinical Site

    Tartu, Estonia · Recruiting

  • Neurocrine Clinical Site

    Milan, Italy · Withdrawn

Showing 40 of 61 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.